Cytori Therapeutics Inc (NASDAQ:CYTX) Short Interest Update

Share on StockTwits

Cytori Therapeutics Inc (NASDAQ:CYTX) was the recipient of a large decline in short interest in the month of June. As of June 30th, there was short interest totalling 152,200 shares, a decline of 33.2% from the May 30th total of 227,800 shares. Based on an average daily volume of 695,900 shares, the short-interest ratio is presently 0.2 days. Currently, 1.2% of the company’s shares are short sold.

A number of equities analysts recently commented on the stock. Maxim Group reaffirmed a “hold” rating on shares of Cytori Therapeutics in a research note on Monday, April 1st. ValuEngine cut shares of Zosano Pharma from a “buy” rating to a “hold” rating in a research note on Wednesday, May 1st.

CYTX remained flat at $$0.24 on Thursday. 259,513 shares of the company were exchanged, compared to its average volume of 620,583. Cytori Therapeutics has a one year low of $0.21 and a one year high of $1.24. The company’s 50 day simple moving average is $0.25. The company has a quick ratio of 0.30, a current ratio of 0.46 and a debt-to-equity ratio of 0.39.

Cytori Therapeutics (NASDAQ:CYTX) last announced its quarterly earnings data on Tuesday, May 14th. The biotechnology company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.02. Cytori Therapeutics had a negative net margin of 242.60% and a negative return on equity of 272.70%. The company had revenue of $0.70 million during the quarter.

A hedge fund recently raised its stake in Cytori Therapeutics stock. Barclays PLC grew its position in shares of Cytori Therapeutics Inc (NASDAQ:CYTX) by 724.4% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 99,747 shares of the biotechnology company’s stock after buying an additional 87,647 shares during the quarter. Barclays PLC owned 0.76% of Cytori Therapeutics worth $29,000 as of its most recent filing with the Securities & Exchange Commission. 2.62% of the stock is currently owned by institutional investors and hedge funds.

About Cytori Therapeutics

Cytori Therapeutics, Inc is a late stage cell therapy company, which engages in the development of autologous cell therapies from adipose tissue, using its proprietary technology, to treat a variety of medical conditions. It offers the Cytori Nanomedicine, Cytori Cell Therapy, and other clinical trials.

Featured Article: Holder of Record

Receive News & Ratings for Cytori Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics and related companies with's FREE daily email newsletter.